Accutar Biotechnology Inc
6 clinical trials · Sponsor
◉ Watch Accutar Biotechnology Inc
| Record | Firm | Date |
|---|---|---|
| A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies (NCT05780034) | Accutar Biotechnology Inc | 2023-06-20 |
| A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (NCT05673109) | Accutar Biotechnology Inc | 2023-02-22 |
| Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer (NCT05654532) | Accutar Biotechnology Inc | 2022-12-29 |
| A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (NCT05489679) | Accutar Biotechnology Inc | 2022-10-01 |
| A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (NCT05241613) | Accutar Biotechnology Inc | 2022-03-16 |
| A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer (NCT05080842) | Accutar Biotechnology Inc | 2021-11-12 |
Track Accutar Biotechnology Inc automatically
Every clearance here is in the API, with alerts when new ones post.